The Effect of proteolysis-targeting chimera (PROTAC) of EZH2 on high grade Serous ovarian Carcinoma.

被引：0
|
作者：
Hachijo, Ryuta [1 ]
Sone, Kenbun [1 ]
Jonouchi, Yuri [1 ]
Ishizaka, Aya [1 ]
Suzuki, Eri [1 ]
Tsuchimochi, Saki [1 ]
Tanimoto, Saki [1 ]
Toyohara, Yusuke [1 ]
Honjo, Harunori [1 ]
Fukuda, Tomohiko [1 ]
Miyamoto, Yuichiro [1 ]
Mori, Mayuyo [1 ]
Oda, Katsutoshi [2 ]
Hirota, Yasushi [1 ]
Osuga, Yutaka [1 ]
机构：
[1] Univ Tokyo, Dept Obstet & Gynecol, Tokyo, Japan
[2] Univ Tokyo, Dept Clin Genom, Tokyo, Japan
来源：
CANCER SCIENCE | 2025年 / 116卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-3205
引用
收藏
页码：1685 / 1685
页数：1
相关论文
共 50 条
  • [21] EZH2 protein expression correlates with high tumor grade in renal cell carcinoma
    Ali, AJ
    Sheehan, CE
    Kallakury, BVS
    Azumi, N
    Ross, JS
    Hayner-Buchan, A
    MODERN PATHOLOGY, 2005, 18 : 125A - 125A
  • [22] Homologous recombination deficiency status-based classification of high-grade serous ovarian carcinoma.
    Matsumura, Noriomi
    Takaya, Hisamitsu
    Takamatsu, Shiro
    Nakai, Hidekatsu
    CLINICAL CANCER RESEARCH, 2020, 26 (13) : 63 - 63
  • [23] Positive PTEN Expression Is Associated with Decreased Survival in Ovarian/Primary Peritoneal High Grade Serous Carcinoma.
    Bakkar, R.
    Urbauer, D.
    Broaddus, R.
    LABORATORY INVESTIGATION, 2011, 91 : 237A - 237A
  • [24] Big data and computational biology method for personalized prognosis of high-grade serous ovarian carcinoma.
    Ow, Ghim Siong
    Tang, Zhiqun
    Ivshina, Anna Vladimirovna
    Kuznetsov, Vladimir Andreevich
    CLINICAL CANCER RESEARCH, 2016, 22
  • [25] A BRCA 1/2 Mutational Signature in Ovarian High Grade Serous Carcinoma
    Dong, F.
    Davineni, P. K.
    Howitt, B. E.
    Beck, A. H.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2016, 18 (06): : 988 - 988
  • [26] A tumor-restricted glycoepitope of podocalyxin correlates with immune evasion in high-grade serous ovarian carcinoma.
    Brassard, Julyanne
    Hernaez, Diana Canals
    Hughes, Michael R.
    Milne, Katy
    Dean, Pamela
    Warren, Mary
    Zhang, Kevin
    Banville, Allyson C.
    Smazynski, Julian
    Bond, David
    Nelson, Brad H.
    Roskelley, Calvin D.
    McNagny, Kelly M.
    JOURNAL OF IMMUNOLOGY, 2022, 208 (01):
  • [27] Studying the effect of germline polymorphisms on somatic hotspot mutations in TP53 for the treatment of high-grade serous ovarian carcinoma.
    de Souza, Cristabelle Madona N.
    Chien, Jeremy
    Madden, Jill
    CLINICAL CANCER RESEARCH, 2018, 24 (15) : 103 - 104
  • [28] Antitumoral Effect of Plocabulin in High Grade Serous Ovarian Carcinoma Cell Line Models
    Heredia-Soto, Victoria
    Escudero, Javier
    Miguel, Maria
    Ruiz, Patricia
    Gallego, Alejandro
    Berjon, Alberto
    Hernandez, Alicia
    Martinez-Diez, Marta
    Zheng, Shuyu
    Tang, Jing
    Hardisson, David
    Feliu, Jaime
    Redondo, Andres
    Mendiola, Marta
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [29] Targeting RAS and downstream signaling in high-grade serous ovarian carcinoma with novel RAS inhibitors
    Mattox, Tyler E.
    Norton, Tiffany S.
    Keeton, Adam B.
    Ward, Antonio B.
    Maxuitenko, Yulia Y.
    Berry, Kristy L.
    Zhu, Bing
    Musiyenko, Alla
    Gavin, Elaine
    Ramirez-Alcantara, Veronica
    Chen, Xi
    Valiyaveettil, Jacob
    Scalici, Jennifer
    Rocconi, Rodney P.
    Piazza, Gary A.
    da Silva, Luciana Madeira
    CANCER RESEARCH, 2019, 79 (13)
  • [30] Targeting BRPF3 moderately reverses olaparib resistance in high grade serous ovarian carcinoma
    Bitler, Benjamin G. G.
    Bailey, Courtney A. A.
    Yamamoto, Tomomi M. M.
    McMellen, Alexandra
    Kim, Hyunmin
    Watson, Zachary L. L.
    MOLECULAR CARCINOGENESIS, 2023, 62 (11) : 1717 - 1730
12345